Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.63), $0.09 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $3 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.